Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future.
angiogenesis inhibitor
drug resistance
immunotherapy
renal cell carcinoma
targeted therapy
tumor microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Mar 2022
09 Mar 2022
Historique:
received:
02
02
2022
accepted:
07
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Angiogenesis inhibitors have been adopted into the standard armamentarium of therapies for advanced-stage renal cell carcinomas (RCC), but more recently, combination regimens with immune checkpoint inhibitors have demonstrated better outcomes. Despite this, the majority of affected patients still eventually experience progressive disease due to therapeutic resistance mechanisms, and there remains a need to develop novel therapeutic strategies. This article will review the synergistic mechanisms behind angiogenesis and immunomodulation in the tumor microenvironment and discuss the pre-clinical and clinical evidence for both clear-cell and non-clear-cell RCC, exploring opportunities for future growth in this exciting area of drug development.
Identifiants
pubmed: 35326557
pii: cancers14061406
doi: 10.3390/cancers14061406
pmc: PMC8946206
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Nat Rev Cancer. 2018 Oct;18(10):619-633
pubmed: 30097614
Oncol Res Treat. 2019;42(3):128-135
pubmed: 30799404
Cell Commun Signal. 2020 Apr 7;18(1):59
pubmed: 32264958
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
N Engl J Med. 2021 Mar 4;384(9):829-841
pubmed: 33657295
Eur J Cancer. 2019 Feb;108:69-77
pubmed: 30648632
Lancet Oncol. 2016 Jul;17(7):883-895
pubmed: 27269741
Lancet Oncol. 2013 May;14(6):552-62
pubmed: 23598172
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Br J Cancer. 2018 May;118(9):1176-1178
pubmed: 29576624
N Engl J Med. 2013 Aug 22;369(8):722-31
pubmed: 23964934
ESMO Open. 2020 Nov;5(6):e001079
pubmed: 33246931
Eur Urol. 2016 May;69(5):866-74
pubmed: 26626617
N Engl J Med. 2021 Apr 8;384(14):1289-1300
pubmed: 33616314
Autoimmunity. 2010 Apr;43(3):204-9
pubmed: 20187707
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
J Clin Oncol. 2022 Mar 17;:JCO2101944
pubmed: 35298296
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
Cancer Res. 1988 May 15;48(10):2641-58
pubmed: 3282647
Bull Cancer. 2020 Jun;107(5S):eS22-eS27
pubmed: 32620212
J Immunother Cancer. 2018 Oct 22;6(1):109
pubmed: 30348216
Vaccines (Basel). 2016 Aug 06;4(3):
pubmed: 27509527
J Clin Oncol. 2017 Feb 20;35(6):591-597
pubmed: 28199818
J Clin Oncol. 2010 May 1;28(13):2144-50
pubmed: 20368553
Cell. 1996 Aug 9;86(3):353-64
pubmed: 8756718
Cancer Immunol Immunother. 2008 Oct;57(10):1553-8
pubmed: 18438662
N Engl J Med. 1986 Dec 25;315(26):1650-9
pubmed: 3537791
J Clin Oncol. 1995 Mar;13(3):688-96
pubmed: 7884429
N Engl J Med. 2007 Jan 11;356(2):185-7
pubmed: 17215538
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
Mol Med Today. 2000 Jan;6(1):15-9
pubmed: 10637570
Eur J Cancer. 2013 Apr;49(6):1287-96
pubmed: 23321547
Nat Med. 1999 Dec;5(12):1359-64
pubmed: 10581076
Cancer Discov. 2012 Sep;2(9):772-4
pubmed: 22969116
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
J Clin Med. 2020 Mar 28;9(4):
pubmed: 32231117
Cancer Res. 2000 Mar 1;60(5):1442-8
pubmed: 10728711
Cell Commun Signal. 2010 Sep 07;8:24
pubmed: 20822533
Oncogene. 2008 Oct 6;27(45):5904-12
pubmed: 18836471
J Clin Oncol. 2020 Jan 1;38(1):63-70
pubmed: 31721643
Kidney Cancer. 2019 Feb 05;3(1):51-61
pubmed: 30854497
Clin Exp Immunol. 2013 Jun;172(3):500-6
pubmed: 23600839
Cell. 2017 May 4;169(4):736-749.e18
pubmed: 28475899
NPJ Breast Cancer. 2020 May 12;6:17
pubmed: 32411819
Cell Commun Signal. 2011 Sep 13;9:18
pubmed: 21914164
Hematol Oncol Clin North Am. 2011 Aug;25(4):835-52
pubmed: 21763970
Blood. 1993 Mar 15;81(6):1414-23
pubmed: 8453090
Immunol Invest. 2006;35(3-4):459-83
pubmed: 16916762
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
J Clin Oncol. 2009 Mar 10;27(8):1280-9
pubmed: 19171708
J Clin Oncol. 2014 Sep 1;32(25):2765-72
pubmed: 25049330
Immunology. 2013 Feb;138(2):105-15
pubmed: 23216602
Breast. 2018 Feb;37:207-214
pubmed: 28363679
Am J Pathol. 1999 Sep;155(3):739-52
pubmed: 10487832
Semin Thromb Hemost. 2010 Apr;36(3):321-31
pubmed: 20490982
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Cancer. 2010 Sep 15;116(18):4256-65
pubmed: 20549832
Vasc Health Risk Manag. 2006;2(3):213-9
pubmed: 17326328
Nat Med. 1995 Feb;1(2):149-53
pubmed: 7585012
Nat Rev Immunol. 2009 Apr;9(4):259-70
pubmed: 19282852
Lancet. 2021 Feb 20;397(10275):695-703
pubmed: 33592176
Urol Clin North Am. 1993 May;20(2):303-21
pubmed: 8493752
Eur Urol. 2020 Aug;78(2):195-206
pubmed: 32376136
J Clin Oncol. 2015 May 1;33(13):1430-7
pubmed: 25452452
J Immunother. 2007 Nov-Dec;30(8):825-30
pubmed: 18049334
N Engl J Med. 2003 Jul 31;349(5):427-34
pubmed: 12890841
Contemp Oncol (Pozn). 2013;17(2):123-7
pubmed: 23788977
Cancer Cell. 2003 Apr;3(4):347-61
pubmed: 12726861
Nature. 2000 Sep 14;407(6801):242-8
pubmed: 11001067
Cell Mol Life Sci. 2020 May;77(9):1745-1770
pubmed: 31690961
Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1
pubmed: 28410911
Nature. 2003 Jun 5;423(6940):593-5
pubmed: 12789320
Free Radic Biol Med. 2011 Aug 15;51(4):893-904
pubmed: 21703345
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Ann Oncol. 2013 Jul;24(7):1730-1740
pubmed: 23625974
Eur Urol Oncol. 2020 Oct;3(5):687-694
pubmed: 31272939
Br J Urol. 1989 Feb;63(2):128-31
pubmed: 2702395
Br J Cancer. 2019 Jan;120(1):16-25
pubmed: 30413826
Lancet. 1999 Jan 2;353(9146):14-7
pubmed: 10023944
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
World J Urol. 2014 Feb;32(1):31-8
pubmed: 23404195
Cancer Immunol Immunother. 2009 Mar;58(3):449-59
pubmed: 18791714
Adv Cancer Res. 1996;69:135-74
pubmed: 8791681
Cancer Immunol Res. 2016 Nov;4(11):895-902
pubmed: 27803050
Invest New Drugs. 1988 Jun;6(2):97-103
pubmed: 3170135
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Lancet Oncol. 2020 Dec;21(12):1563-1573
pubmed: 33284113
J Clin Oncol. 2017 Jun 1;35(16):1764-1769
pubmed: 28113029
Nature. 1997 Apr 17;386(6626):671-4
pubmed: 9109485
J Clin Oncol. 2010 May 1;28(13):2137-43
pubmed: 20368558
N Engl J Med. 2007 May 31;356(22):2271-81
pubmed: 17538086
Oncogene. 2010 Feb 25;29(8):1093-102
pubmed: 19946335
Clin Genitourin Cancer. 2021 Oct;19(5):434-446
pubmed: 34006498
Ann N Y Acad Sci. 2013 May;1284:1-5
pubmed: 23651186
J Clin Oncol. 2017 Dec 1;35(34):3851-3858
pubmed: 28678668
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
N Engl J Med. 2007 Jan 11;356(2):125-34
pubmed: 17215530
Nat Rev Immunol. 2008 Jan;8(1):74-80
pubmed: 18064049
J Clin Oncol. 2012 Apr 20;30(12):1371-7
pubmed: 22430274
Genome Biol. 2016 Nov 17;17(1):231
pubmed: 27855702
Clin Cancer Res. 2015 Feb 15;21(4):687-92
pubmed: 25501578
Nature. 2000 Sep 14;407(6801):249-57
pubmed: 11001068
Adv Immunol. 2006;90:51-81
pubmed: 16730261
Ann Oncol. 2017 Jun 01;28(6):1339-1345
pubmed: 28327953
Cells. 2019 May 17;8(5):
pubmed: 31108880
J Clin Oncol. 2009 Jul 10;27(20):3312-8
pubmed: 19451442
Lancet Oncol. 2018 Mar;19(3):405-415
pubmed: 29439857
J Clin Oncol. 2014 May 10;32(14):1412-8
pubmed: 24687826
Nat Commun. 2016 Aug 30;7:12624
pubmed: 27571927
Cancer Res. 2000 Mar 1;60(5):1388-93
pubmed: 10728704
J Clin Oncol. 2009 Aug 1;27(22):3584-90
pubmed: 19487381